A Lasocki1,2,3, F Gaillard2, A Gorelik4,5, M Gonzales6,7. 1. From the Department of Cancer Imaging (A.L.), Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia arian.lasocki@petermac.org. 2. Department of Radiology (A.L., F.G.). 3. Monash Imaging (A.L.), Monash Health, Clayton, Victoria, Australia. 4. Melbourne EpiCentre (A.G.). 5. Departments of Medicine (A.G.). 6. Department of Anatomical Pathology (M.G.), The Royal Melbourne Hospital, Parkville, Victoria, Australia. 7. Pathology (M.G.), The University of Melbourne, Parkville, Victoria, Australia.
Abstract
BACKGROUND AND PURPOSE: The 2016 revision of the World Health Organization Classification of Tumors of the Central Nervous System mandates codeletion of chromosomes 1p and 19q for the diagnosis of oligodendroglioma. We studied whether conventional MR imaging features could predict 1p/19q status. MATERIALS AND METHODS: Patients with previous 1p/19q testing were identified through pathology department records, typically performed on the basis of an oligodendroglial component on routine histology; 69 patients met the inclusion criteria. Preoperative imaging of patients with grade II or III gliomas was retrospectively assessed by 2 neuroradiologists, blinded to the 1p/19q status. Thirteen MR imaging features were first assessed in a small initial cohort (n = 10), after which the criteria were narrowed for the remaining patients as a validation cohort. RESULTS: There was 85% agreement between radiologists for the overall prediction of 1p/19q status in the validation cohort, with an accuracy of 84%. The presence of >50% T2-FLAIR mismatch and calcification was found to be the most useful for predicting 1p/19q status. The >50% T2-FLAIR mismatch variable was demonstrated in 14 tumors and had 100% specificity for identifying a noncodeleted tumor (P = .001), with 97% interobserver correlation. Calcification was visualized in 7 tumors, 6 of which were 1p/19q codeleted (specificity, 97%; P = .006), with 100% interobserver correlation. CONCLUSIONS: The presence of >50% T2-FLAIR mismatch is highly predictive of a noncodeleted tumor, while calcifications suggest a 1p/19q codeleted tumor. If formal 1p/19q testing is not possible, a combined MR imaging-histologic assessment may improve the diagnostic accuracy over histology alone.
BACKGROUND AND PURPOSE: The 2016 revision of the World Health Organization Classification of Tumors of the Central Nervous System mandates codeletion of chromosomes 1p and 19q for the diagnosis of oligodendroglioma. We studied whether conventional MR imaging features could predict 1p/19q status. MATERIALS AND METHODS:Patients with previous 1p/19q testing were identified through pathology department records, typically performed on the basis of an oligodendroglial component on routine histology; 69 patients met the inclusion criteria. Preoperative imaging of patients with grade II or III gliomas was retrospectively assessed by 2 neuroradiologists, blinded to the 1p/19q status. Thirteen MR imaging features were first assessed in a small initial cohort (n = 10), after which the criteria were narrowed for the remaining patients as a validation cohort. RESULTS: There was 85% agreement between radiologists for the overall prediction of 1p/19q status in the validation cohort, with an accuracy of 84%. The presence of >50% T2-FLAIR mismatch and calcification was found to be the most useful for predicting 1p/19q status. The >50% T2-FLAIR mismatch variable was demonstrated in 14 tumors and had 100% specificity for identifying a noncodeleted tumor (P = .001), with 97% interobserver correlation. Calcification was visualized in 7 tumors, 6 of which were 1p/19q codeleted (specificity, 97%; P = .006), with 100% interobserver correlation. CONCLUSIONS: The presence of >50% T2-FLAIR mismatch is highly predictive of a noncodeleted tumor, while calcifications suggest a 1p/19q codeleted tumor. If formal 1p/19q testing is not possible, a combined MR imaging-histologic assessment may improve the diagnostic accuracy over histology alone.
Authors: P Darvishi; P P Batchala; J T Patrie; L M Poisson; M-B Lopes; R Jain; C E Fadul; D Schiff; S H Patel Journal: AJNR Am J Neuroradiol Date: 2020-04-23 Impact factor: 3.825
Authors: Rajan Jain; Derek R Johnson; Sohil H Patel; Mauricio Castillo; Marion Smits; Martin J van den Bent; Andrew S Chi; Daniel P Cahill Journal: Neuro Oncol Date: 2020-07-07 Impact factor: 12.300
Authors: P P Batchala; T J E Muttikkal; J H Donahue; J T Patrie; D Schiff; C E Fadul; E K Mrachek; M-B Lopes; R Jain; S H Patel Journal: AJNR Am J Neuroradiol Date: 2019-01-31 Impact factor: 3.825
Authors: J C Benson; D Summerfield; C Carr; P Cogswell; S Messina; J V Gompel; K Welker Journal: AJNR Am J Neuroradiol Date: 2020-03-26 Impact factor: 3.825
Authors: Sohil H Patel; Prem P Batchala; Thomas J Eluvathingal Muttikkal; Sergio S Ferrante; James T Patrie; Camilo E Fadul; David Schiff; M Beatriz Lopes; Rajan Jain Journal: J Neurooncol Date: 2021-03-04 Impact factor: 4.130